Adjuvant Mitotane for Adrenocortical Cancer—A Recurring Controversy

Por Huang, Hui, Fojo, Tito
Publicado em 2008

How Much Is Life Worth: Cetuximab, Non–Small Cell Lung Cancer, and the $440 Billion Question

Por Fojo, Tito, Grady, Christine
Publicado em 2009

BEZ235: When Promising Science Meets Clinical Reality

Por Pongas, Georgios, Fojo, Tito
Publicado no Oncologist (2016)

Taccalonolides: A microtubule stabilizer poses a new puzzle with old pieces

Por Sackett, Dan L., Fojo, Tito
Publicado em 2011

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Por Veytsman, Irina, Nieman, Lynnette, Fojo, Tito
Publicado em 2009

Editor's Note …Clinical Trial Reports: A New Section

Por Fojo, Tito, Bates, Susan, Chabner, Bruce A.
Publicado em 2012

Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients

Por Prasad, Vinay, Massey, Paul R., Fojo, Tito
Publicado em 2014

Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer

Por Fojo, Tito, Amiri-Kordestani, Laleh, Bates, Susan E.
Publicado em 2011

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

Por Blagosklonny, Mikhail V., Robey, Robert, Bates, Susan, Fojo, Tito
Publicado em 2000

Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials

Por Burotto, Mauricio, Manasanch, Elisabet E., Wilkerson, Julia, Fojo, Tito
Publicado no Oncologist (2015)

Microtubule disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells

Por Huff, Lyn M., Sackett, Dan L., Poruchynsky, Marianne S., Fojo, Tito
Publicado em 2010

Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage

Por Stein, Wilfred D., Yang, James, Bates, Susan E., Fojo, Tito
Publicado em 2008

Cancer Drugs in the United States: Justum Pretium—The Just Price

Por Kantarjian, Hagop M., Fojo, Tito, Mathisen, Michael, Zwelling, Leonard A.
Publicado em 2013

Multiplying therapies and reducing toxicity in metastatic melanoma

Por Massey, Paul R, Prasad, Vinay, Figg, William D, Fojo, Tito
Publicado no Cancer Biol Ther (2015)

Radiofrequency Ablation for Tumor-Related Massive Hematuria

Por Neeman, Ziv, Sarin, Shawn, Coleman, Jonathan, Fojo, Tito, Wood, Bradford J.
Publicado em 2005

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

Por Madan, Ravi A., Gulley, James L., Fojo, Tito, Dahut, William L.
Publicado em 2010

MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy

Por Patterson, Erin E., Holloway, Alisha K., Weng, Julie, Fojo, Tito, Kebebew, Electron
Publicado em 2010

Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example

Por Burotto, Mauricio, Wilkerson, Julia, Stein, Wilfred, Motzer, Robert, Bates, Susan, Fojo, Tito
Publicado em 2014

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting

Por Massey, Paul R., Wang, Ruibin, Prasad, Vinay, Bates, Susan E., Fojo, Tito
Publicado no Oncologist (2016)

Radiofrequency Ablation of Adrenal Tumors and Adrenocortical Carcinoma Metastases

Por Wood, Bradford J., Abraham, Jame, Hvizda, Julia L., Alexander, H. Richard, Fojo, Tito
Publicado em 2003